Suppr超能文献

希腊作为控制 COVID-19 感染传播模型的经验。

The Experience of Greece as a Model to Contain COVID-19 Infection Spread.

机构信息

International Institute of Anticancer Research, Kapandriti, Greece;

Fourth Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.

出版信息

In Vivo. 2021 Mar-Apr;35(2):1285-1294. doi: 10.21873/invivo.12380.

Abstract

The severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) emerged in late 2019 and has caused a pandemic known as corona virus disease 2019 (COVID-19), responsible for the death of more than 2 million people worldwide. The outbreak of COVID-19 has posed an unprecedented threat on human lives and public safety. The aim of this review is to describe key aspects of the bio-pathology of the novel disease, and discuss aspects of its spread, as well as targeted protective strategies that can help shape the outcome of the present and future health crises. Greece is used as a model to inhibit SARS-COV-2 spread, since it is one of the countries with the lowest fatality rates among nations of the European Union (E.U.), following two consecutive waves of COVID-19 pandemic. Furthermore, niche research technological approaches and scientific recommendations that emerged during the COVID-19 era are discussed.

摘要

严重急性呼吸系统综合症冠状病毒 2 型(SARS-CoV-2)于 2019 年末出现,并引发了一种被称为 2019 年冠状病毒病(COVID-19)的大流行,导致全球超过 200 万人死亡。COVID-19 的爆发对人类生命和公共安全构成了前所未有的威胁。本综述旨在描述这种新型疾病的生物病理学的关键方面,并讨论其传播的各个方面,以及有针对性的保护策略,这些策略有助于塑造当前和未来健康危机的结果。希腊被用作抑制 SARS-CoV-2 传播的模型,因为它是欧盟(EU)国家中在经历了 COVID-19 大流行的两波疫情后死亡率最低的国家之一。此外,还讨论了 COVID-19 时代出现的利基研究技术方法和科学建议。

相似文献

1
The Experience of Greece as a Model to Contain COVID-19 Infection Spread.
In Vivo. 2021 Mar-Apr;35(2):1285-1294. doi: 10.21873/invivo.12380.
2
A main event and multiple introductions of SARS-CoV-2 initiated the COVID-19 epidemic in Greece.
J Med Virol. 2021 May;93(5):2899-2907. doi: 10.1002/jmv.26778. Epub 2021 Feb 23.
3
The Greek Response to COVID-19: A True Success Story from an IBD Perspective.
Inflamm Bowel Dis. 2020 Jul 17;26(8):1144-1148. doi: 10.1093/ibd/izaa143.
4
Epidemiology and precision of SARS-CoV-2 detection following lockdown and relaxation measures.
J Med Virol. 2021 Apr;93(4):2374-2384. doi: 10.1002/jmv.26731. Epub 2020 Dec 29.
8
A mini-review on the effects of COVID-19 on younger individuals.
Exp Biol Med (Maywood). 2021 Feb;246(3):293-297. doi: 10.1177/1535370220975118. Epub 2020 Nov 19.
10
Practical laboratory considerations amidst the COVID-19 outbreak: early experience from Singapore.
J Clin Pathol. 2021 Apr;74(4):257-260. doi: 10.1136/jclinpath-2020-206563. Epub 2020 Mar 20.

引用本文的文献

7
Analysis of Diagnostic Modalities in Hospital-admitted Patients Evaluated for COVID-19.
In Vivo. 2022 May-Jun;36(3):1316-1324. doi: 10.21873/invivo.12832.
10

本文引用的文献

3
Vaccinating against covid-19 in people who report allergies.
BMJ. 2021 Jan 18;372:n120. doi: 10.1136/bmj.n120.
4
Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit?
Br J Anaesth. 2021 Mar;126(3):e106-e108. doi: 10.1016/j.bja.2020.12.020. Epub 2020 Dec 17.
5
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
6
Genetic mechanisms of critical illness in COVID-19.
Nature. 2021 Mar;591(7848):92-98. doi: 10.1038/s41586-020-03065-y. Epub 2020 Dec 11.
7
Meteorological factors, governmental responses and COVID-19: Evidence from four European countries.
Environ Res. 2021 Mar;194:110596. doi: 10.1016/j.envres.2020.110596. Epub 2020 Dec 9.
9
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验